

Stanford

Maximilian Haist

Postdoctoral Scholar, Microbiology and Immunology

Bio

BIO

Dr. Haist is a clinician scientist who explores the tumor microenvironment of advanced skin cancer patients to identify predictive biomarkers and immunological signatures using single-cell multiplexing technologies. As a Ph.D. student, Dr. Haist investigated the role of tumor hypoxia and the adenosine system in patients with melanoma brain metastases treated with combined radiochemotherapy. Currently, Dr Haist is a Postdoctoral Fellow in Dr. Garry Nolan's lab and comes with interest in multiplex technologies to analyze the organization of effective anti-tumor immune responses within the tumor microenvironment.

HONORS AND AWARDS

- TRANSMED Jumpstart Fellowship, Else-Kröner Fresenius Foundation (2020)
- Walter-Benjamin Fellowship, German Research Foundation (2022)

PROFESSIONAL EDUCATION

- Staatsexamen, Johannes Gutenberg Universität Mainz (2019)
- Doctor of Medicine, Johannes Gutenberg Universität Mainz (2021)
- MD, Johannes-Gutenberg University Mainz, Germany and University of Zurich, Switzerland , Medicine (2019)
- Dr. med., Department of Radiation Oncology and Radiotherapy, University Medical Center of the Johannes-Gutenberg University Mainz, Germany , Melanoma Immunotherapy (2021)

STANFORD ADVISORS

- Garry Nolan, Postdoctoral Faculty Sponsor

Research & Scholarship

LAB AFFILIATIONS

- Garry Nolan, Nolan Lab (8/14/2022)

Publications

PUBLICATIONS

- **T cell-mediated curation and restructuring of tumor tissue coordinates an effective immune response.** *Cell reports*
Hickey, J. W., Haist, M., Horowitz, N., Caraccio, C., Tan, Y., Rech, A. J., Baertsch, M. A., Rovira-Clavé, X., Zhu, B., Vazquez, G., Barlow, G., Agmon, E., Goltsev, et al
2023; 42 (12): 113494
- **Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.** *Journal for immunotherapy of cancer*
Haist, M., Stege, H., Rogall, F., Tan, Y., von Wasielewski, I., Klespe, K. C., Meier, F., Mohr, P., Kähler, K. C., Weichenthal, M., Hauschild, A., Schadendorf, D., Ugurel, et al
2023; 11 (9)

- **Response to primary chemoradiotherapy of locally advanced oropharyngeal carcinoma is determined by the degree of cytotoxic T cell infiltration within tumor cell aggregates.** *Frontiers in immunology*
Haist, M., Kaufmann, J., Kur, I. M., Zimmer, S., Grabbe, S., Schmidberger, H., Weigert, A., Mayer, A.
2023; 14: 1070203
- **Neutrophil-Specific Knockdown of beta 2 Integrins Impairs Antifungal Effector Functions and Aggravates the Course of Invasive Pulmonary Aspergillosis** *FRONTIERS IN IMMUNOLOGY*
Haist, M., Ries, F., Gunzer, M., Bednarczyk, M., Siegel, E., Kuske, M., Grabbe, S., Radsak, M., Bros, M., Teschner, D.
2022; 13: 823121
- **Second opinion and self-efficacy in German skin cancer patients** *JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT*
Stege, H., Schneider, S., Forschner, A., Eigentler, T., Nashed, D., Huening, S., Lehr, S., Meiss, F., Kaatz, M., Kuchen, R., Kaehler, K. C., Haist, M., Grabbe, et al
2024
- **Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia: A Retrospective, Real-Life Analysis in a Tertiary Center in Germany** *JOURNAL OF CLINICAL MEDICINE*
Stege, H., Haist, M., Schultheis, M., Pawlowski, J., Wittmann, M., Grabbe, S., Butsch, F.
2024; 13 (16)
- **Tumor-stroma contact ratio - a novel predictive factor for tumor response to chemoradiotherapy in locally advanced oropharyngeal cancer.** *Translational oncology*
Kaufmann, J., Haist, M., Kur, I. M., Zimmer, S., Hagemann, J., Matthias, C., Grabbe, S., Schmidberger, H., Weigert, A., Mayer, A.
2024; 46: 102019
- **Novel methods of multiparametric tissue diagnostics** *ONKOLOGIE*
Mayer, A., Haist, M.
2023; 29 (12): 1069-1077
- **Spatial Dissection of the Bone Marrow Microenvironment in Multiple Myeloma By High Dimensional Multiplex Tissue Imaging**
Baertsch, M., Brobeil, A., Hickey, J., Haist, M., Poos, A., Lu, G., Kuswanto, W., Schuerch, C., Voehringer, H., Huber, W., Mechttersheimer, G., Mueller-Tidow, C., Schirmacher, et al
AMER SOC HEMATOLOGY.2023
- **Quantification of invasion patterns as a predictive factor for the therapeutic response of oropharyngeal squamous cell carcinoma to radiochemotherapy**
Kaufmann, J., Haist, M., Kur, I., Zimmer, S., Hagemann, J., Matthias, C., Grabbe, S., Schmidberger, H., Weigert, A., Mayer, A.
SPRINGER HEIDELBERG.2023: S35-S36
- **Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?** *Cancer metastasis reviews*
Haist, M., Stege, H., Kuske, M., Bauer, J., Klumpp, A., Grabbe, S., Bros, M.
2023
- **Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry.** *Cancers*
Haist, M., Stege, H., Lang, B. M., Tsochataridou, A., Salzmann, M., Mohr, P., Schadendorf, D., Ugurel, S., Placke, J., Weichenthal, M., Gutzmer, R., Leiter, U., Kaatz, et al
2022; 14 (22)
- **Impaired regulatory T cell-dendritic cell interactions contribute to autoimmunity in leukocyte adhesion deficiency type-1.** *JCI insight*
Klaus, T., Wilson, A. S., Vicari, E., Hadaschik, E., Klein, M., Helbich, S. S., Kamenjarin, N., Hodapp, K., Schunke, J., Haist, M., Butsch, F., Probst, H. C., Enk, et al
2022
- **The Role of the Immune Phenotype in Tumor Progression and Prognosis of Patients with Mycosis Fungoides: A Quantitative Immunohistology Whole Slide Approach** *CELLS*
Aulasevich, N., Haist, M., Foersch, S., Weidenthaler-Barth, B., Mailaender, V.
2022; 11 (22)
- **Protease- and cell type-specific activation of protease-activated receptor 2 in cutaneous inflammation** *JOURNAL OF THROMBOSIS AND HAEMOSTASIS*
Fleischer, M., Roehrig, N., Raker, V. K., Springer, J., Becker, D., Ritz, S., Bros, M., Stege, H., Haist, M., Grabbe, S., Haub, J., Becker, C., Reyda, et al
2022